SARS-CoV-2 - Camostat mesylate - Therapeutic Candidates

SARS-CoV-2 - Camostat mesylate - Therapeutic Candidates


Camostat is a serine protease inhaler used, in the form of camostat mesilate, for the treatment of various pathologies such as certain cancers or fibrosis in kidney diseases.
CoV-2-CoRNA exploits the cell entry receptor protein, angiotensin II converting enzyme (ACE-2), to access and infect human cells. The interaction between ACE-2 and the lead protein is not in the active site. This process requires the serine protease TMPRSS2. Camostat mesilate is a potent inhibitor of serine protease. Through research on the SARS-CoV-2 coronavirus and its closely related cell entry mechanism, it has been shown that the cellular entry of SARS-CoV-2 can be blocked by camostat mesilate. In mice, camostat mesilate administered at concentrations similar to the clinically achievable concentration in humans reduced mortality from SARS-CoV-2 infection from 100% to 30-35%. In addition, another study showed that camostat mesilate reduced SARS-CoV-2 infection of Calu-3 cells.

Search result : 54 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 32
  • Inhibitor/Antagonist/Agonist 37
  • Biochemicals 17


Cat#
Description
Cond.
Price Bef. VAT
orb638792-50mg
 50mg 
orb638792-10mg
 10mg 
orb760972-10mg
 10mg 
orb760972-50mg
 50mg 
M2487-10mg
 10mg 
AG00E8MK-1g
 1g 
M2487-50mg
 50mg 
332-10779-1
 5mg 
332-10779-6
 200mg 
AG00E8MK-250mg
 250mg 
abx282569-10mg
 10mg 
M2487-100mg
 100mg 
332-10779-2
 10mg 
332-10779-3
 25mg 
332-10779-4
 50mg 
332-10779-5
 100mg 
abx282569-50mg
 50mg 
10-2196-10mg
 10mg 
B2082-100mg
 100mg